Key Highlights

  • Endeavour Group (ASX:EDV) remains under pressure as investors question the long-term outlook for its hotel and gaming operations.
  • Regulatory reforms targeting gaming machines across multiple Australian states are increasing uncertainty around hotel Earnings growth.
  • Cost-of-living pressures, changing consumer behaviour, and ESG-related concerns continue weighing on sentiment toward the hospitality segment.
  • Dan Murphy’s and BWS continue providing defensive retail liquor exposure, though broader consumer sector challenges remain in focus.

 

ResMed (ASX: RMD) has delivered a quarterly result that gives ASX healthcare stocks investors meaningful new data to assess one of the most important global Australian-listed medical device companies. After navigating an unusually turbulent few years marked by competitor product recall windfalls, then weight-loss drug-driven sentiment whiplash, ResMed's Q3 2026 results provide the latest evidence on whether the company's core sleep and respiratory care Franchise is back on a steady growth path. With the broader ASX healthcare sector under valuation pressure and global medical technology stocks rebuilding investor confidence, the implications of these results extend well beyond ResMed itself. For investors weighing exposure to ASX healthcare stocks, understanding how ResMed is positioned post-Q3 is one of the most consequential analytical exercises of the current reporting cycle.

Why This Topic Matters Now

ResMed is one of the largest healthcare names on the ASX, with global operations spanning the United States, Europe, and Asia Pacific. The company is a global leader in sleep apnoea devices, including continuous positive airway pressure (CPAP) machines, and adjacent respiratory care products. Its share price moves significantly influence ASX healthcare sector benchmarks and global medical technology indices.

The Q3 2026 results matter for several reasons. They provide a critical update on Demand trends following years of unusual dynamics including a major competitor recall, Supply chain normalisation, and weight-loss drug speculation around obesity-related sleep apnoea. They also offer fresh insight into operating margins, free Cash Flow, and Capital allocation in an environment where investors are placing renewed emphasis on quality earnings.

For Australian shares investors, ResMed represents a benchmark for understanding global medical technology dynamics, including pricing power, R&D-driven competitive moats, and the resilience of healthcare demand through economic cycles. The Q3 result, in conjunction with company commentary, will shape sentiment toward the entire ASX healthcare sector for the months ahead.

Company Background

ResMed was founded in Sydney in 1989 and has grown into a global Market Leader in sleep and respiratory medicine. The company is dual-listed on the New York Stock Exchange and the ASX, with US-based operational headquarters and significant Manufacturing operations in Singapore, Australia, and the United States. Sleep devices, including CPAP and bilevel machines and associated masks and accessories, represent the bulk of Revenue. Respiratory care, including ventilators and other devices, contributes a smaller but meaningful share. Software-as-a-service, offered to home medical equipment providers and care facilities, is a growing strategic focus.

ResMed has built one of the strongest competitive moats in global medical technology through decades of innovation, deep clinical relationships, and scale advantages in manufacturing and distribution. The company's product pipeline has consistently delivered improved patient comfort, smaller form factors, integrated cloud connectivity, and digital health features. Its mask portfolio, which generates highly Recurring Revenue as patients regularly replace consumables, anchors a particularly attractive economic profile.

The company's competitive position was strengthened materially in 2021 when its primary competitor Philips initiated a major product recall. ResMed captured significant Market Share during this period, generating exceptional revenue growth. The subsequent normalisation of the competitive landscape as Philips returned to the market created a period of uncertainty, as did renewed investor focus on whether GLP-1 weight loss drugs could reduce long-term demand for sleep apnoea treatment.

Key Catalysts and Recent Developments

The Q3 2026 results delivered insight on several key dimensions. Underlying revenue growth in the core sleep and respiratory care Business demonstrated continued momentum, with both new patient starts and replacement device demand contributing to top-line expansion. Mask growth, often viewed as the highest-quality recurring revenue stream, also performed encouragingly.

Margin performance has been a critical investor focus given the inflationary cost pressures of recent years. Q3 commentary on gross margins, Operating Expense discipline, and free cash flow provided important data on whether the company is successfully navigating cost normalisation. Leveraged operating margins through revenue growth are particularly important to the long-term thesis.

The competitive environment appears to be stabilising. Philips' return to the sleep apnoea market is now well established, and the impact on ResMed's market share appears more measured than initial bearish scenarios suggested. ResMed's product innovation pipeline, including new mask designs and next-generation device platforms, continues to support competitive position.

The GLP-1 weight loss drug narrative has evolved meaningfully. Initial fears that drugs like semaglutide and tirzepatide would dramatically reduce sleep apnoea prevalence have been moderated by clinical data showing that while weight loss can improve sleep apnoea, it rarely eliminates the condition. ResMed's own messaging has emphasised that the global undiagnosed sleep apnoea population vastly exceeds current treatment volumes, suggesting GLP-1 adoption may even support disease awareness and treatment seeking.

Financial and Valuation Considerations

ResMed's financial profile remains among the strongest in the ASX healthcare sector. Gross margins are healthy by medical device standards, supported by scale advantages and product mix benefits. Operating margins have benefited from revenue growth leveraging a relatively Fixed Cost base. Free cash flow generation is robust, supporting both ongoing R&D Investment and Shareholder returns through dividends and Buybacks.

The Balance Sheet is conservatively managed. Net Debt levels are modest, providing flexibility for both organic growth investment and selective acquisitions. Capital allocation discipline has been a hallmark of management's approach, with capital returns to shareholders complementing strategic investment.

Valuation has been a key debate. ResMed's share price has moved through significant cycles in recent years, reflecting changing sentiment about market share dynamics, GLP-1 risks, and broader healthcare sector multiples. Following the Q3 results, the share price reflects a complex interplay of factors including operational delivery, competitive position, and macro sentiment around interest rates and Growth Stocks.

Compared to global medical device peers, ResMed trades at multiples that reflect its quality characteristics including market leadership, recurring revenue, and innovation capability. Compared to broader ASX healthcare stocks, the Valuation Premium reflects ResMed's superior return on invested capital and growth profile.

Risks and Counterarguments

The bear case on ResMed has multiple components. GLP-1 weight loss drug adoption could over time reduce the addressable population for sleep apnoea treatment, even if the impact appears more limited than initial fears suggested. Sustained reductions in obesity prevalence would gradually reduce sleep apnoea incidence over years.

Competitive intensity from Philips and other emerging players could pressure pricing and market share. While the immediate post-recall period was favourable for ResMed, sustained competitive pressure may result in more measured growth and margin trajectory.

Healthcare reimbursement risks vary by geography. Changes to CPAP reimbursement policies in major markets including the United States, Germany, and Japan could affect device demand and pricing. Regulatory changes affecting home medical equipment providers, key intermediaries between ResMed and patients, also matter.

Foreign exchange risks affect reported earnings. ResMed reports in US dollars but operates globally, with currency movements influencing both reported revenue growth and translation of foreign earnings.

The bull case rests on the structural drivers of sleep medicine demand. Sleep apnoea remains massively underdiagnosed globally, with estimates suggesting only a small fraction of affected adults are currently treated. Increasing awareness, improved diagnostic tools including home sleep tests, and broader recognition of sleep apnoea's links to cardiovascular and metabolic health all support long-term demand growth.

What Investors Should Watch Next

Investors monitoring ResMed should focus on several near-term indicators. Quarterly device and mask growth rates by geography, particularly in the United States where the largest share of revenue is generated, will provide ongoing momentum signals. New patient setup data, where disclosed, indicates underlying disease awareness and diagnosis trends.

Margin trajectory deserves continued scrutiny. Gross margin movements reflect product mix, competitive pricing, and manufacturing cost dynamics. Operating Margin reflects operating Leverage and R&D investment intensity.

GLP-1 sector developments remain relevant. Real-world evidence on whether and how weight loss drugs affect sleep apnoea diagnosis and treatment patterns will continue to evolve. Continued ResMed messaging on the topic, supported by clinical evidence, will shape sentiment.

Capital allocation decisions including Dividend trajectory, buyback activity, and any Acquisition announcements should be monitored. Strategic decisions in the software and digital health space could also influence the Long-term Growth profile.

Outlook

The outlook for ResMed appears constructive following Q3 2026 results. The core sleep and respiratory care franchise continues to demonstrate growth momentum supported by structural disease prevalence trends, ongoing innovation, and competitive position. Margin performance and free cash flow generation remain healthy, supporting both continued investment and shareholder returns. The competitive landscape has stabilised and the GLP-1 narrative has matured, removing some of the recent uncertainty that pressured the share price.

For long-term investors in ASX healthcare stocks, ResMed remains one of the highest-quality global medical technology franchises accessible on the Australian stock market. The combination of market leadership, recurring revenue, innovation capability, and disciplined capital allocation provides a strong foundation for continued compounding. Valuation is not cheap by absolute standards, but the quality characteristics support a premium multiple over time.

In the near term, the share price will continue to respond to quarterly operational data, competitive announcements, and broader healthcare sector sentiment. Investors should expect periodic Volatility around results and regulatory news, but the structural investment thesis appears intact. For patient investors with a multi-year horizon, ResMed offers exposure to a defensive growth franchise with global reach and strong execution track record.

The ResMed story will continue to be a benchmark for how global medical technology companies navigate competitive transitions, regulatory environments, and macro shifts. The Q3 2026 results provide encouraging evidence that the company is back on a steady track, even as markets remain alert to evolving risks.